↓ Skip to main content

Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.

Overview of attention for article published in Blood transfusion = Trasfusione del sangue, July 2020
Altmetric Badge

Mentioned by

blogs
1 blog
twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
2 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.
Published in
Blood transfusion = Trasfusione del sangue, July 2020
DOI 10.2450/2020.0314-19
Pubmed ID
Authors

Ballester-Servera, Carme, Jimenez-Marco, Teresa, Morell-Garcia, Daniel, Quetglas-Oliver, Miguel, Bautista-Gili, Antonia M, Girona-Llobera, Enrique, Carme Ballester-Servera, Teresa Jimenez-Marco, Daniel Morell-Garcia, Miguel Quetglas-Oliver, Antonia M Bautista-Gili, Enrique Girona-Llobera

Abstract

Pathogen reduction technology (PRT) may damage platelet (PLT) components. To study this, metabolic activity and haemostatic function of buffy coat (BC) PLT concentrates, with or without riboflavin and UV light PRT treatment, were compared. Twenty-four BC PLT concentrates, leukoreduced and diluted in additive solution, were grouped into 12 type-matched pairs, which were pooled and divided into 12 non-PRT-treated BC PLT concentrates (control units) and 12 riboflavin and UV PRT-treated BC PLT concentrates (test units). Haemostatic function and metabolic parameters were monitored by thrombelastography at days 1, 3, 7 and 14 post collection in both PLT groups. Loss of PLT discoid shape, glucose consumption, lactate production, and decrease in pH were greater in the PRT-treated PLTs than in control PLTs over time (p<0.001). PLT haemostatic function evaluated by clot strength was also significantly weaker in PRT-treated PLTs compared with the excellent clot quality of control PLTs at day 7 (maximum amplitude: 41.27 vs 64.27; p<0.001), and even at day 14 (21.16 vs 60.39; p<0.001) of storage. Pathogen reduction technology treatment accelerates and increases platelet storage lesion, resulting in glucose depletion, lactate accumulation, PLT acidification, and discoid shape loss. The clots produced by control PLTs at day 14 were still remarkably strong, whereas at day 7 PRT-treated PLTs produced weaker clots compared to the control group. Clinical trials investigating the efficacy of PRT-treated PLTs transfused at the end of the storage period (day 7), when the in vitro clot strength is weaker, are needed.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 50%
Other 1 50%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 50%
Medicine and Dentistry 1 50%